RxDoctor Payments Data

William Zillweger, MD

Internal Medicine · Pittsburgh, PANPI 1285607002

Payments from drug & device makers

$5,394in general payments, 2019–2025

Across 357 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$1K
  • Johnson & Johnson$968
  • Novo Nordisk$553
  • Medtronic$329
  • Amgen$323
  • AstraZeneca$234
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,34799%
  • Gifts$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,394 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,683
Medicare patients
132
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban295$115,506
XareltoRivaroxaban88$28,605
AptiomEslicarbazepine Acetate24$22,811
JardianceEmpagliflozin47$22,744
Nurtec OdtRimegepant Sulfate11$20,663
MyrbetriqMirabegron51$12,721
EntrestoSacubitril/Valsartan15$9,121
Mirabegron ErMirabegron13$4,361
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$3,516
Sucralfate18$3,462
Potassium Chloride64$2,888
Metoprolol Succinate176$2,830
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc24$2,390
Unifine Safecontrol Pen NeedlePen Needle,dual Safety,diabetc40$2,306
Rosuvastatin Calcium70$2,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$124$136,169306 claims
Johnson & JohnsonXarelto$968$28,60588 claims
Boehringer IngelheimJardiance$15$22,74447 claims
NovartisEntresto$122$9,12115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →